Literature DB >> 19428174

Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro.

Stephanie Oger1, Delphine Behr-Roussel, Diane Gorny, Thierry Lebret, Yves Denoux, Laurent Alexandre, François Giuliano.   

Abstract

BACKGROUND: Lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) are highly prevalent in aging men and are strongly linked. Alpha₁-blockers such as alfuzosin are effective monotherapies for LUTS. Phosphodiesterase type 5 (PDE5) inhibitors such as tadalafil are the first-line treatment for ED. Both drugs act by two different mechanisms of action on common urogenital target organs and, thus, may have additive effects.
OBJECTIVES: We evaluated in vitro the effects of alfuzosin, tadalafil, and the combination of both on human detrusor and prostatic smooth muscle. DESIGN, SETTING, AND PARTICIPANTS: Prostatic and bladder tissue were obtained from patients (n=20 and n=17, respectively) undergoing cystoprostatectomy for bladder cancer. MEASUREMENTS: In organ baths, isolated prostatic strips and isolated bladder strips were incubated with vehicle, tadalafil (10⁻⁶ M and 10⁻⁵ M), alfuzosin (3×10⁻⁸ M or 10⁻⁶ M and 10⁻⁵ M) or a combination. Concentration-response curves (CRCs) to norepinephrine were generated on prostatic strips and detrusor strips precontracted with carbachol. Strips were also submitted to electrical field stimulation (EFS). RESULTS AND LIMITATIONS: When alfuzosin and tadalafil were combined, the maximal relaxation to norepinephrine on carbachol-precontracted detrusor strips was significantly increased compared with tadalafil alone, and EFS-induced detrusor contractions were better inhibited compared with each compound alone. Tadalafil significantly inhibited norepinephrine-induced prostatic strip contractions by reducing the maximal effect, whereas alfuzosin shifted the CRC of norepinephrine to the right. Combining both tadalafil and alfuzosin resulted in a greater relaxant effect. Likewise, the combination was more effective at reducing EFS-induced contractions compared with each compound alone.
CONCLUSIONS: The combination of alfuzosin and tadalafil exerts an additive effect of inhibiting adrenergic smooth muscle tone of prostatic tissue and EFS-induced detrusor contractions and conversely, of enhancing adrenergic relaxation of detrusor precontracted with carbachol. These experiments provide experimental support for the clinical investigation of the combination of α1-blockers and PDE5 inhibitors in the treatment of LUTS.
Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428174     DOI: 10.1016/j.eururo.2009.04.039

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  10 in total

Review 1.  An overview of prostate diseases and their characteristics specific to Asian men.

Authors:  Shu-Jie Xia; Di Cui; Qi Jiang
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

2.  An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Zhe Jin; Zhi-Chao Zhang; Ji-Hong Liu; Jun Lu; Yu-Xin Tang; Xiang-Zhou Sun; Wei-Dong Song; Bing Gao; Ying-Lu Guo; Zhong-Cheng Xin
Journal:  Asian J Androl       Date:  2011-05-23       Impact factor: 3.285

Review 3.  Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Authors:  Selim Cellek; Norman E Cameron; Mary A Cotter; Christopher H Fry; Dapo Ilo
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

4.  Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3.

Authors:  Qingfeng Yu; Christian Gratzke; Yiming Wang; Annika Herlemann; Christian Maximilian Sterr; Beata Rutz; Anna Ciotkowska; Xiaolong Wang; Frank Strittmatter; Christian G Stief; Martin Hennenberg
Journal:  Br J Pharmacol       Date:  2018-04-29       Impact factor: 8.739

5.  Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction.

Authors:  Sidney Glina; Felipe Placco Araujo Glina
Journal:  Ther Adv Urol       Date:  2013-08

Review 6.  Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2012-09       Impact factor: 3.923

7.  Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial.

Authors:  Rommel Prata Regadas; Ricardo Reges; João Batista Gadelha Cerqueira; Daniel Gabrielle Sucupira; Iatagan Rocha Josino; Emmanuel Almeida Nogueira; Francisco Vagnaldo F Jamacaru; Manoel Odorico de Moraes; Lúcio Flávio Gonzaga Silva
Journal:  Int Urol Nephrol       Date:  2012-10-30       Impact factor: 2.370

Review 8.  Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations.

Authors:  Bader Alsaikhan; Khalid Alrabeeah; Serge Carrier
Journal:  Int J Gen Med       Date:  2014-06-12

9.  Inhibition by tadalafil of contractility of isolated nonpregnant human myometrium.

Authors:  Sumalya Sen; Anitha Thomas; Saibal Das; Jayanta Kumar Dey; Abraham Peedicayil; Vinotha Thomas; Jacob Peedicayil
Journal:  J Pharmacol Pharmacother       Date:  2016 Oct-Dec

10.  Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis.

Authors:  Jianwei Cui; Dehong Cao; Yunjin Bai; Jiahao Wang; Shan Yin; Wuran Wei; Yunfei Xiao; Jia Wang; Qiang Wei
Journal:  Front Med (Lausanne)       Date:  2021-10-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.